Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Biopharma scores a $5bn quarter as another big year builds for venture financing.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.